Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 12,820 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication, Pregnancy Clear all
Completed No phase listed Observational

Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients

NCT03156244
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Results available

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

NCT03250832
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 2, 2026, 1:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

NCT00572793
View directory record Official record
Conditions
Preeclampsia
Interventions
Not listed
Lead sponsor
Carl Weiner, MD
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 2, 2026, 1:01 AM EDT
Completed No phase listed Observational

Fetal Outcomes Among Pregnant Emergency General Surgery Patients

NCT05085353
View directory record Official record
Conditions
Pregnancy Complications, Acute Appendicitis, Acute Cholecystitis, Biliary Pancreatitis, Bowel Obstruction, Acute Diverticulitis
Interventions
non-obstetric acute general surgical disease
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Terminated No phase listed Observational

Virtue® Male Sling Fixation Study

NCT01170728
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Coloplast Virtue® Male Sling
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

NCT00006028
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
30
States / cities
Los Gatos, California • Tampa, Florida • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

NCT00322465
View directory record Official record
Conditions
Urethritis
Interventions
Doxycycline, Placebo, Tinidazole, Azithromycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Male only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

NCT01218867
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Melanoma, Renal Cancer
Interventions
Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 2, 2026, 1:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

PopSci CHW4CervixHealth

NCT07336134
View directory record Official record
Conditions
Cervical Cancer, Hpv, Human Papilloma Virus, HPV Infection
Interventions
Evalyn® Brush, Copan Floqswab, CHW4CervicalHealth
Device · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 3 Interventional

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

NCT03614234
View directory record Official record
Conditions
Fabry Disease
Interventions
pegunigalsidase alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Fetal Genome Profiling Via Trophoblast Cells

NCT03832634
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
Fetal Genome Profiling.
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 2, 2026, 1:01 AM EDT
Terminated Not applicable Interventional Results available

Foley Catheter for Labor Induction in Women With Term and Near Term Membrane Rupture

NCT00290199
View directory record Official record
Conditions
Fetal Membranes, Premature Rupture, Labor, Induced/IS
Interventions
Transcervical Foley catheter
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years to 55 Years · Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Newark, Delaware • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

NCT01031381
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
RAD001, bevacizumab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 2, 2026, 1:01 AM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Cooperstown, New York • Winston-Salem, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional Results available

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

NCT02502071
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
sodium bicarbonate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Recruiting Phase 3 Interventional

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT03952299
View directory record Official record
Conditions
Overactive Bladder Syndrome, Neuropathic Bladder
Interventions
Oxybutynin Transdermal Patch, Oral Oxybutynin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years to 8 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Pragmatic Approach to Lowering the Risk of Diabetes Mellitus After A Diagnosis of Gestational Diabetes Mellitus

NCT04615351
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Metformin
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 2, 2026, 1:01 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Ovarian Reserve After Cancer: Longitudinal Effects

NCT02467231
View directory record Official record
Conditions
Effects of Chemotherapy, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
11 Years to 35 Years · Female only
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)

NCT01158131
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Balance after Baby Lifestyle Intervention Program
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional Results available

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

NCT04124939
View directory record Official record
Conditions
Overactive Bladder
Interventions
OnabotulinumtoxinA 100 Units
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Greensboro, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 2, 2026, 1:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Carcinoma
Interventions
Avelumab, Sacituzumab Govitecan (SG), M6223, NKTR-255, JB100
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

NCT02807636
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 2, 2026, 1:01 AM EDT
Recruiting No phase listed Observational

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

NCT01802034
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Not applicable Interventional Results available

Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

NCT01367834
View directory record Official record
Conditions
Turner Syndrome
Interventions
somatotropin
Drug
Lead sponsor
Rebecca Knickmeyer Santelli, PhD
Other
Eligibility
11 Months to 13 Months · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 2, 2026, 1:01 AM EDT